The invention relates to a powder composition comprising spherically agglomerated lactose particles comprising radially arranged prism-like lactose particles, at least one active pharmaceutical ingredient (API) and optionally at least one additive, its manufacture and its use for inhalation applications.

According to some embodiments, a carrier for reducing a likelihood of a pathogen binding to cell structures of a host comprises a core, surface features extending from an exterior surface of the core, wherein the surface features are configured to bind to target areas of cell structures of the host to at least partially block the pathogen from binding to said target areas as a result of competitive inhibition, and a plurality of binding sites along the exterior surface, wherein the binding sites are configured to attract at least one portion of the pathogen, wherein the binding sites are recognizable by the pathogen and are able to be bound by the pathogen, thereby at least partially immobilizing the pathogen and reducing the likelihood of the pathogen binding to target areas of cell structures of the host.

A solid co-amorphous dispersion of valsartan according to the invention is characterized in that in the amorphous solid phase it contains valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, an d at least one non-toxic amphiphilic solvent that solvates valsartan and co-former molecules, wherein the content of valsartan exceeds 40 mol % and 65 wt %, and the dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. A method for synthetizing a solid co-amorphous dispersion of valsartan by mixing valsartan with a co-former, pouring a solvent over the mixture and evaporating the solvent, wherein the physical mixture of valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, and at least one non-toxic amphiphilic solvent is formed and subjected to mixing and homogenization in a condensed-phase, at the temperature range of 20-100° C., preferably 45-100° C., whereby excess of the solvent used is stripped off at the temperature range of 20-100° C., preferably 45-100° C., to give a final product in form of a solvated solid co-amorphous dispersion of valsartan, co-former and the solvent, which dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. The use of solvated solid co-amorphous dispersions of valsartan as described above, obtained as described above, in medicine and pharmacy, especially for treatment of hypertension and COVID-19 disease caused by SARS-CoV-2 virus, as a ternary formulation of valsartan, nicotinamide and a non-toxic amphiphilic solvent, preferably ethanol, n-propanol or i-propanol, characterized by increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan, and having a dual action, resulting from the synergy of ingredients supporting the therapeutic effect of valsartan. The disclosed solid dispersion according to the invention is characterized by higher solubility in comparison with that of pure valsartan, and therefore an increased bioavailability of this drug. A number of benefits results therefrom for patients (lower amount of active substance ingested), the pharmaceutical industry (lower effective dose of the active substance in preparations, resulting in reduction of production costs) and the environment (less amount of the active substance and its metabolites not absorbed by patients and released into the environment). The appropriate selection o

The present disclosure relate to feed ingredients and formulated feed, methods for their manufacture, and uses thereof in nutritional applications such as in aquaculture, terrestrial animal feed, and human nutrition. The feed ingredient compositions comprise lysed microbial cells with a small aspect ratio and triglyceride oil.

Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.

The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of a medicated fish feed. The medicated fish feed comprises fish feed granules or pellets coated with a composition comprising a neonicotinoid such as imidacloprid and a carrier having a high apparent digestibility coefficient such as a processed/cooked corn protein concentrate.

This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate individuals.

An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg is disclosed. The dosage unit consists of: (a) 5-100 wt. % of coated particles comprising 50-99 wt. % of a core particle and 1-50 wt. % of a coating that envelops the core particle, said coating consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-50 wt. % of buffering agent; 15-80 wt. % of branched glucan; 0-78 wt. % of other pharmaceutically acceptable ingredients; and (b) 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 20 μg of the partus control substance and having a pH buffer range of 3.5-5.7.

The present invention provides a method for safe and efficacious administration of esketamine.